Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors
Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell disease
Fort Collins, CO, June 21, 2022 – Cetya Therapeutics, Inc. today announced the addition of Dr. Anthony Wutoh, Provost and Chief Academic Officer of Howard University, to its Board of Directors. Dr. Wutoh received a B.A. in Biochemistry from the University of Maryland Baltimore County in 1987, a B.S. in Pharmacy and a Ph.D. in Pharmacy Administration (Pharmacoepidemiology) at the University of Maryland, Baltimore School of Pharmacy. Dr. Wutoh has various research interests including pharmacoepidemiology, international health, health services/outcomes research and evaluation of large population databases, particularly in the area of AIDS and HIV infection in older patients. Dr. Wutoh has led and participated in international programs including sponsored projects (USAID, CDC, PEPFAR, etc.). Dr. Wutoh has been a practicing pharmacist in Maryland since 1990 and has worked in various settings including hospital, retail, consulting and commercial pharmacy as well as academia. His other areas of interest and expertise include minority access to novel therapies, medication compliance, post-marketing assessment, clinical trial protocol and evaluation, survival analyses and the role of stress in the functioning of health care professionals. Dr. Wutoh is the recipient of various awards and acclamations including the 1998 Excellence Award for Professor in the Division of Pharmacy, College of Pharmacy, Nursing and Allied Health Sciences and the 2007 Distinguished Faculty Award from the Howard University Pharmacy Alumni Association.
“I am excited to be joining the Board of Cetya, a dynamic company with the goal of helping a patient population in dire need of improved therapeutics for Sickle Cell Disease (SCD). I am pleased to offer my assistance to those efforts,” stated Dr. Wutoh.
Cetya is advancing CT-101 for the treatment of SCD by increasing the level of fetal hemoglobin in SCD patients, improving oxygen transport, and mitigating the debilitating side effects which characterize this disease. We have conducted preliminary studies which show improved performance versus existing therapies while minimizing toxicity and associated side effects.
Sickle cell disease and related conditions such as the b-thalassemias are among the most common genetic disorders globally, affecting millions of people. 7% of the world’s population carries an abnormal hemoglobin gene.
“We are thrilled by the addition of Dr. Anthony Wutoh to Cetya’s Board of Directors” stated Ron A. Lowy, Chairman. “Tony brings a wealth of scientific experience and depth of understanding of the challenges faced by sickle cell patients.
About Cetya Theraeutics
Cetya Therapeutics, Inc. is a development stage pharmaceutical company developing histone deacetylase inhibitors structurally based on the marine natural product Largazole. Cetya has the exclusive worldwide rights to the histone deacetylase (HDAC) inhibitor platform and patent estate developed in the laboratory of Dr. Robert M. Williams at CSU. Cetya has a portfolio of analogs, including CT-102, to evaluate in solid tumor indications and has selected a lead candidate for treatment of hemoglobin disorders such as Sickle Cell Disease. Cetya is seeking corporate partners to assist in the advancement of its analog portfolio in a number of different therapeutic indications. For more information on Cetya, please visit our website at www.cetyatherapeutics.com or contact Cliff Hendrick at firstname.lastname@example.org